“The US Food and Drug Administration will prioritize lifesaving drugs. All others, pre-Investigational New Drug (IND), IND, type b, type c and pre-approval inspections should expect delays,” Nawal Ouzren, Sensorion CEO and director, told the audience at the McDermott Will & Emery European Health and Life Sciences Symposium held in Paris on 2 April.
“What we are seeing is just the beginning. [Around] 3500 people were laid off [from the FDA], but there will be more.”
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?